Bioactive Lipid Mediators in Cardiopulmonary Pharmacology
- 1st Edition, Volume 97 - May 24, 2023
- Editors: Darryl C Zeldin, John Seubert
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 0 5 7 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 0 5 8 - 9
Bioactive Lipid Mediators in Cardiopulmonary Pharmacology, Volume 97 updates readers on topics surrounding Bioactive lipid mediators. These mediators are involved in a vast arra… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteBioactive Lipid Mediators in Cardiopulmonary Pharmacology, Volume 97 updates readers on topics surrounding Bioactive lipid mediators. These mediators are involved in a vast array of signaling pathways that regulate both physiological and pathophysiological responses. Chapters in this new release include Cyclooxygenases and Vascular Function, Cyclooxygenases and Platelet Function, Eicosanoids and Cardiomyopathies, Cytochrome P450 Bioactive Lipids in the Heart, Epoxide Hydrolase and Leukotoxin in the Heart and Lung, Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response, Bioactive Lipids in Hypertension, Cytochrome P450 Metabolites and Angiogenesis, 20-Hydroxyeicosatetraenoic Acid and Vascular Function, and more.
Other critical sections cover Cytochrome P450 Eicosanoids and the Brain, Omega-3 Oxylipids, Resolvins, Lipoxins and Inflammation, Endocannabinoids as Bioactive Metabolites, and Oxylipins and Aspirin Exacerbated Respiratory Disease.
- Provides reviews from world experts in the field of bioactive lipid mediators
- Focuses on current topics, with an emphasis on the development of novel therapeutics
- Covers a diverse range of bioactive lipids derived from COX, LOX or CYP-mediated metabolism of omega-3 and omega-6 PUFAs
Clinical and basic researchers involved in drug discovery and pathophysiology
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: Bioactive lipids in hypertension
- Abstract
- 1: Introduction
- 2: Bioactive lipid pathways and metabolites
- 3: Human genetic studies implicating bioactive lipids in hypertension
- 4: Bioactive lipids and vascular function in hypertension
- 5: Kidney regulation by bioactive lipids in hypertension
- 6: Inflammation and bioactive lipids in hypertension
- 7: Conclusion
- References
- Chapter Two: Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response
- Abstract
- 1: Introduction
- 2: Role of CYP450-epoxygenase, ω-hydroxylase, and soluble epoxide in the modulation of adenosine-induced vascular response in mice
- 3: Modulation of adenosine-induced vascular response and the role of CYP450-epoxygenase, ω-hydroxylase, and soluble epoxide hydrolase in high salt-diet-fed mice
- 4: Modulation of coronary reactive hyperemia and the role of adenosine A2A receptor, CYP450-epoxygenase, soluble epoxide hydrolase, ω-hydroxylase, cyclooxygenase, lipoxygenase, and PPAR-γ in mice
- 5: Role of plasma/isolated heart perfusate oxylipins in the modulation of coronary reactive hyperemia in mice and cardiovascular diseases
- 6: Clinical trials of soluble epoxide hydrolase inhibitors and adenosine receptors agonists
- 7: Conclusion
- References
- Chapter Three: Cyclooxygenases and platelet functions
- Abstract
- 1: Introduction
- 2: COX-dependent eicosanoid biosynthesis
- 3: Prostanoid receptors and platelet function
- 4: Single nucleotide polymorphic variants of prostanoid receptors and functions
- 5: COX-dependent prostanoid biosynthesis in platelet-cellular crosstalk
- 6: Inhibition of COX-dependent platelet function
- 7: Conclusion
- References
- Chapter Four: The roles of eicosanoids in myocardial diseases
- Abstract
- 1: Introduction
- 2: Eicosanoids generation and metabolism
- 3: CYP450 derived eicosanoids and myocardial diseases
- 4: COX derived eicosanoids and cardiomyopathy
- 5: The LOX derived eicosanoids and cardiomyopathy
- 6: Conclusion
- References
- Chapter Five: Cardioprotective mechanisms of cytochrome P450 derived oxylipins from ω-3 and ω-6 PUFAs
- Abstract
- 1: Introduction
- 2: Epoxyeicosatrienoic acids (EETs) and Dihydroxyeicosatrienoic acids (DHETs)
- 3: Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)
- 4: Conclusion
- Conflict of interest
- References
- Further reading
- Chapter Six: 20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond
- Abstract
- 1: Introduction
- 2: 20-HETE biosynthesis
- 3: 20-HETE receptors
- 4: G protein-coupled receptor 75 (GPR75)
- 5: G protein-coupled receptor 40 (GPR40)/free fatty acid receptor-1 (FFAR-1)
- 6: Vascular bioactions of 20-HETE
- 7: Vascular smooth muscle cells
- 8: Blood pressure and vascular tone
- 9: Vascular remodeling
- 10: Angiogenesis vs Arteriogenesis
- 11: Drug development: 20-HETE synthesis inhibitors, agonists and receptor blockers
- 12: Conclusion
- References
- Chapter Seven: Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease
- Abstract
- 1: Introduction
- 2: Acute inflammation is protective; chronic, non-resolving inflammation is maladaptive
- 3: Non-resolving inflammation is an underpinning of cardiovascular diseases
- 4: RvD2 promotes resolution of inflammation via GPR18
- 5: Role of the RvD2:GPR18 axis in cardiovascular physiology and disease
- 6: Conclusion
- References
- Chapter Eight: Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation
- Abstract
- 1: Introduction
- 2: P450 synthesis and metabolism
- 3: Biological actions
- 4: Cerebrovascular disorders and other brain pathological conditions
- 5: Targeting sEH in neurological disorders
- 6: Conclusion
- Conflict of interest
- References
- Chapter Nine: Lipid mediators generated by the cytochrome P450—Epoxide hydrolase pathway
- Abstract
- 1: Introduction
- 2: PUFA epoxide biology
- 3: PUFA diol biology
- 4: Epoxide: Diol balance in physiology
- 5: Epoxide: Diol balance in pathology
- 6: Impact of dietary PUFAs on health
- 7: Conclusion
- References
- Chapter Ten: Role of omega-3 and omega-6 endocannabinoids in cardiopulmonary pharmacology
- Abstract
- 1: Introduction
- 2: CB1 receptor and CB2 receptor
- 3: Pharmacokinetics and pharmacodynamics of cannabinoids
- 4: Omega-6 endocannabinoids
- 5: Other related lipids
- 6: Omega-3 endocannabinoids
- 7: Metabolism of endocannabinoids by eicosanoid synthesizing enzymes
- 8: Conclusion
- References
- Chapter Eleven: The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD)
- Abstract
- 1: Introduction
- 2: Oxylipin formation and role in asthma
- 3: Oxylipin involvement in N-ERD
- 4: N-ERD treatments and their potential effects on oxylipins
- 5: Conclusion
- Conflict of interest
- References
- No. of pages: 462
- Language: English
- Edition: 1
- Volume: 97
- Published: May 24, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780323950572
- eBook ISBN: 9780323950589
DZ
Darryl C Zeldin
Dr. Darryl Zeldin is a Senior Investigator and the Scientific Director at the National Institute of Environmental Health Sciences, National Institutes of Health (NIH/NIEHS). He obtained his MD degree from Indiana University School of Medicine, completed his Internship/Residency in Internal Medicine at Duke University Medical Center and his Pulmonary/Critical Care Fellowship at Vanderbilt University Medical Center. His research program focuses on understanding the role of eicosanoids in regulating pulmonary and cardiovascular function. He is a Fellow in the American College of Chest Physicians, a Fellow in the American Heart Association and is an elected member of the American Society for Clinical Investigation and American Association of Physicians. He has co-authored over 380 primary peer-reviewed articles and his work has been cited over 33,000 times. He has mentored over 85 post-baccalaureate fellows, graduate students, medical students, postdoctoral research fellows and clinical research fellows. As the NIEHS Scientific Director, he is responsible for one of the largest intramural research programs at the NIH with over 600 scientists in 11 Departments and 17 Core Facilities.
Affiliations and expertise
National Institutes of Health/National Institute of Environmental Health Services, NC, USAJS
John Seubert
Dr. John M. Seubert is a Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta. He obtained his MSc in Biological Sciences (Simon Fraser University), PhD in Pharmacology and Toxicology (University of Western Ontario) and a Postdoctoral Fellowship in Cardiovascular Pharmacology at the National Institute of Environmental Health Sciences, National Institutes of Health (NIH/NIEHS). His research program focuses on the biological role essential fatty acids have in cardiac homeostasis and pathology. A central theme involves understanding the role the cytochrome P450 system has within the cell to assist in the development novel drug targets and strategies to limit injury. He is an adjunct professor in the Department of Pharmacology, Faculty of Medicine and Dentistry at the University of Alberta. He has co-authored over 78 primary peer-reviewed articles. He has mentored over 90 undergraduate students, pharmacy students, graduate students, postdoctoral research fellows and research fellows. His research has been funded by the Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada.
Affiliations and expertise
University of Alberta Faculty of Medicine and Dentistry, Edmonton, CanadaRead Bioactive Lipid Mediators in Cardiopulmonary Pharmacology on ScienceDirect